BAM
ABCL icon

Belpointe Asset Management’s AbCellera Biologics ABCL Stock Holding History

Belpointe Asset Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-5,300
Closed -$40K – 622
2023
Q1 		$40K Buy
5,300
+1,896
+56% +$17.2K ﹤0.01% 1847
2022
Q4 		$34.5K Buy
+3,404
New +$39.3K ﹤0.01% 1832

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Belpointe Asset Management's ABCL Position: Q2 2023 in Review

Belpointe Asset Management sold out of AbCellera Biologics (ABCL) in Q2 2023, closing a stake of 5,300 shares — an estimated $40K sold.

Belpointe Asset Management first reported a position in ABCL in Q4 2022 and held it in 2 quarters. The position peaked at $40K in Q1 2023. 169 funds tracked by Wall St. Rank hold ABCL as of Q2 2023.

  • Belpointe Asset Management reported no remaining AbCellera Biologics position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 5,300 AbCellera Biologics shares in Q2 2023, an estimated $40K.
  • Belpointe Asset Management first reported a position in AbCellera Biologics in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's AbCellera Biologics position peaked at $40K in Q1 2023.
  • 169 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.